Rejuvenate Bio is pursuing one of biotechnology’s most ambitious goals: treating the root causes of aging itself.
Founded by a team of scientists and entrepreneurs from Harvard, MIT, and Caltech, and co-founded by renowned geneticist George Church, Rejuvenate is developing gene therapies designed to combat multiple age-related diseases with a single treatment.
The company has already raised more than $40 million from venture-capital firms including VCapital, Digitalis Ventures, Kendall Capital Partners, and KdT Ventures. Now it’s seeking additional capital from individual investors like you.
At its core, Rejuvenate is built around the idea that many chronic diseases share common biological causes. Rather than creating separate drugs for heart disease, kidney disease, metabolic disorders, and other conditions, the company is developing gene therapies that target the aging process itself.
Its treatments use carefully selected genes delivered through viral vectors to help restore healthier cellular function. In simple terms, the goal is to reprogram the body to function more like it did when it was younger.
The company’s strategy is somewhat unique. That’s because it’s pursuing both animal-health and human-health opportunities. Rejuvenate initially focused on companion animals, particularly dogs suffering from age-related conditions such as heart disease and metabolic disorders.
Management believes this creates a faster path to commercialization while simultaneously generating valuable data that can support future human therapies. In fact, the company often describes its approach as a way to “double-dip” on research, with canine studies helping advance both veterinary and human programs.
The market opportunity is substantial. The global gene therapy market is already worth more than $10 billion annually and is expected to grow rapidly as more therapies reach commercialization.
Meanwhile, the broader longevity and healthy-aging market is measured in the hundreds of billions of dollars, fueled by aging populations and rising healthcare costs. The pet-health market is also sizable, valued at roughly $300 billion. Owners are increasingly willing to spend significant amounts to extend the lives and health of their animals. By targeting both human and veterinary applications, Rejuvenate has multiple pathways to create value.
To make money, Rejuvenate’s business model combines product sales, development partnerships, milestone payments, and royalties. The company has secured more than $130 million in contracted development and commercial milestone payments, and management projects royalty revenue beginning later this decade. This approach could enable the company to generate revenue well before its broader vision of human anti-aging therapies reaches the market.
Rejuvenate’s platform has produced disease-reversal results in dogs and life-extension results in mice, providing early evidence that its approach may work across multiple species.
The company has received more than $13 million in non-dilutive funding from the U.S. Department of Defense and U.S. Special Operations Command to explore applications related to endurance, recovery, and resilience in both humans and working dogs. It’s also received more than $5 million in cumulative payments and in-kind services from partners.